NCT06304025View on ClinicalTrials.gov

Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

August 31, 2025

Conditions
Graft Versus Host Disease
Interventions
BIOLOGICAL

Wharton's jelly mesenchymal stem cells (WJ-MSCs)

Four doses of 1x10 6 of thawed allogeneic WJ-MSCs or expanding allogeneic WJ-MSCs / kg at 1, 4, 11, and 18 days

All Listed Sponsors
collaborator

Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud - IDCBIS

OTHER

lead

Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle

OTHER

NCT06304025 - Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment | Biotech Hunter | Biotech Hunter